GO:0016212 L-kynurenine:2-oxoglutarate transaminase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016212 describes the enzymatic activity that transfers the amino group from L-kynurenine to 2-oxoglutarate, yielding kynurenate and L-glutamate.
• This activity is catalyzed by kynurenine aminotransferases (KATs), which exist as multiple isoenzymes in mammalian tissues, including brain, liver, kidney, and heart.
• The reaction is pyridoxal 5'-phosphate (PLP)-dependent and also acts on 3-hydroxykynurenine to form xanthurenate.
• KATs are key regulators of the kynurenine pathway, balancing the production of neuroactive metabolites such as kynurenic acid.
• Dysregulation of kynurenine aminotransferase activity has been implicated in neurological and psychiatric disorders, making it a target for mechanistic studies.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise interrogation of KAT gene function in health and disease.
Description
L-kynurenine:2-oxoglutarate transaminase activity (GO:0016212) is a molecular function that catalyzes the transamination of L-kynurenine to kynurenate, using 2-oxoglutarate as the amino acceptor. This reaction is a critical branch point in the kynurenine pathway, which is the major route of tryptophan catabolism in mammals. The enzyme responsible, kynurenine aminotransferase (KAT), is widely distributed across tissues, with distinct isoenzymes identified in rat and human brain, liver, and other organs. The activity is pyridoxal 5'-phosphate (PLP)-dependent and also accepts 3-hydroxykynurenine as a substrate, producing xanthurenate. Researchers study GO:0016212 because it directly influences the levels of kynurenic acid, a neuroactive metabolite that modulates glutamatergic and cholinergic neurotransmission. Alterations in KAT activity have been linked to neurological and psychiatric conditions, making this activity a focal point for understanding brain function and disease. Moreover, the enzyme's presence in peripheral tissues such as heart and liver suggests broader metabolic roles. This article provides a comprehensive overview of the biological process, cellular components, and molecular mechanism of GO:0016212, along with key genes, disease associations, and research methodologies. It is intended for researchers seeking to investigate this activity using advanced CRISPR-based models and functional genomics.
L-kynurenine:2-oxoglutarate transaminase activity At A Glance
| GO ID | GO:0016212 |
|---|---|
| GO term | L-kynurenine:2-oxoglutarate transaminase activity |
| Ontology | Molecular function |
| Synonym | Kynurenine aminotransferase activity; kynurenine--oxoglutarate aminotransferase activity; kynurenine transaminase (cyclizing) |
| Major function | Transamination of L-kynurenine to kynurenate using 2-oxoglutarate as amino acceptor |
| Cofactor | Pyridoxal 5'-phosphate (PLP) |
| Substrates | L-kynurenine, 3-hydroxykynurenine, 2-oxoglutarate |
| Products | Kynurenate, xanthurenate, L-glutamate |
| Tissue distribution | Brain, liver, kidney, heart, small intestine |
What Is GO:0016212?
GO:0016212, L-kynurenine:2-oxoglutarate transaminase activity, is defined as the catalysis of the reaction: 2-oxoglutarate + L-kynurenine = H2O + kynurenate + L-glutamate. The product 4-(2-aminophenyl)-2,4-dioxobutanoate is converted into kynurenate by a spontaneous reaction. The enzyme also acts on 3-hydroxykynurenine to form xanthurenate. This activity is synonymous with kynurenine aminotransferase activity and represents a key step in the kynurenine pathway.
Why Is L-kynurenine:2-oxoglutarate transaminase activity Important in Cell Biology?
GO:0016212 is important because it governs the production of kynurenic acid, a neuroactive metabolite that antagonizes NMDA receptors and modulates neuronal excitability. By regulating the balance between neurotoxic and neuroprotective kynurenine pathway metabolites, this activity influences brain health and disease. Additionally, its role in peripheral tissues such as the heart and liver highlights its broader metabolic significance. Understanding this activity is essential for developing therapeutic strategies targeting neurological and psychiatric disorders.
• Regulates kynurenic acid synthesis, a key neuroprotective metabolite.
• Influences glutamatergic neurotransmission via NMDA receptor antagonism.
• Implicated in neurological disorders such as schizophrenia and epilepsy.
• Plays a role in tryptophan catabolism and NAD+ synthesis.
• Expressed in multiple tissues, including brain, liver, and heart.
• Target for drug development in neuropsychiatric conditions.
• Provides a branch point between neurotoxic and neuroprotective pathways.
• Enables metabolic flexibility through multiple isoenzymes.
• Potential biomarker for inflammatory and immune responses.
• Facilitates comparative studies across species due to conserved activity.
What Happens During L-kynurenine:2-oxoglutarate transaminase activity?
Substrate Binding and Transamination
In simple terms: The enzyme grabs L-kynurenine and 2-oxoglutarate and swaps an amino group between them.
The reaction begins with the binding of L-kynurenine and 2-oxoglutarate to the active site of kynurenine aminotransferase. The enzyme uses pyridoxal 5'-phosphate (PLP) as a cofactor to transfer the amino group from L-kynurenine to 2-oxoglutarate, forming kynurenate and L-glutamate. This step is highly specific and requires the presence of PLP for catalytic activity.
Formation of Kynurenate
In simple terms: After the swap, a unstable intermediate quickly turns into kynurenate.
The initial product of transamination is 4-(2-aminophenyl)-2,4-dioxobutanoate, which undergoes spontaneous cyclization to form kynurenate. This non-enzymatic step ensures the efficient production of kynurenate, a key neuroactive metabolite.
Alternative Substrate: 3-Hydroxykynurenine
In simple terms: The enzyme can also act on a similar molecule to make xanthurenate.
In addition to L-kynurenine, the enzyme can use 3-hydroxykynurenine as a substrate, converting it to xanthurenate. This broad substrate specificity suggests a role in regulating multiple branches of the kynurenine pathway.
Tissue-Specific Isoenzymes
In simple terms: Different versions of the enzyme exist in different tissues, each with unique properties.
Multiple kynurenine aminotransferase isoenzymes have been identified in rat and human tissues, including brain, liver, and heart. These isoenzymes may exhibit distinct kinetic properties and substrate preferences, allowing for tissue-specific regulation of kynurenine metabolism.
Key Genes Involved in GO:0016212 L-kynurenine:2-oxoglutarate transaminase activity
The following genes encode proteins that exhibit L-kynurenine:2-oxoglutarate transaminase activity or are closely related to its function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KYAT1 (CCBL1) | Encodes kynurenine aminotransferase I, a PLP-dependent enzyme that catalyzes the transamination of kynurenine to kynurenate | Major isoenzyme in brain and liver; target for neurological studies |
| KYAT2 (AADAT) | Encodes kynurenine aminotransferase II, also involved in lysine and tryptophan metabolism | Expressed in brain and liver; potential role in metabolic disorders |
| KYAT3 (CCBL2) | Encodes kynurenine aminotransferase III, a mitochondrial enzyme | Contributes to kynurenic acid synthesis in brain |
| GOT2 | Aspartate aminotransferase, mitochondrial; may exhibit overlapping substrate specificity | Model for studying enzyme promiscuity |
| GPT | Alanine aminotransferase; not directly involved but shares PLP-dependent mechanism | Control for transaminase studies |
| AADAT | 2-Aminoadipate aminotransferase, also acts on kynurenine | Bifunctional enzyme in lysine and tryptophan metabolism |
| CCBL1 | Cysteine conjugate beta-lyase 1, identical to KYAT1 | Alternative name for KAT I |
| CCBL2 | Cysteine conjugate beta-lyase 2, identical to KYAT3 | Alternative name for KAT III |
| TDO2 | Tryptophan 2,3-dioxygenase, upstream of kynurenine production | Regulates substrate availability |
| IDO1 | Indoleamine 2,3-dioxygenase 1, upstream of kynurenine production | Influences kynurenine levels |
| IDO2 | Indoleamine 2,3-dioxygenase 2, paralog of IDO1 | Less characterized, potential regulatory role |
| KMO | Kynurenine 3-monooxygenase, competes for kynurenine | Balances neurotoxic vs neuroprotective branches |
| KYNU | Kynureninase, degrades kynurenine and 3-hydroxykynurenine | Affects substrate availability |
| HAAO | 3-Hydroxyanthranilate 3,4-dioxygenase, downstream of kynurenine | Influences NAD+ synthesis |
| QPRT | Quinolinate phosphoribosyltransferase, downstream enzyme | Links to NAD+ metabolism |
| PLP | Pyridoxal 5'-phosphate, cofactor for KATs | Essential for catalytic activity |
How Is L-kynurenine:2-oxoglutarate transaminase activity Regulated?
Kynurenine aminotransferase activity is regulated at multiple levels. Substrate availability of L-kynurenine is controlled by upstream enzymes such as indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). The enzyme's activity is also influenced by pyridoxal 5'-phosphate (PLP) availability, as PLP is an essential cofactor. Tissue-specific expression of isoenzymes further modulates activity, with distinct forms in brain, liver, and heart. Additionally, competitive substrates like 3-hydroxykynurenine can affect the flux through this reaction.
L-kynurenine:2-oxoglutarate transaminase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KYAT1 | Schizophrenia, epilepsy | Knockout mouse, neuronal cell lines |
| KYAT2 | Metabolic disorders | Liver-specific knockout |
| KYAT3 | Neurodegeneration | Brain organoids, CRISPR knock-in |
| KMO | Huntington's disease | Overexpression models |
| IDO1 | Cancer, inflammation | Tumor xenografts |
Neurological and Psychiatric Disorders
Alterations in kynurenine aminotransferase activity have been observed in neurological and psychiatric conditions. Reduced kynurenic acid levels, potentially due to decreased KAT activity, have been implicated in schizophrenia and epilepsy. The enzyme's role in modulating NMDA receptor function suggests that dysregulation could contribute to excitotoxicity and neuronal dysfunction.
Metabolic and Inflammatory Diseases
Kynurenine pathway dysregulation is associated with inflammatory conditions and metabolic disorders. Kynurenine aminotransferase activity in peripheral tissues such as liver and heart may influence systemic kynurenine levels and contribute to disease pathology. Further research is needed to fully elucidate these connections.
From L-kynurenine:2-oxoglutarate transaminase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KYAT1 affect kynurenic acid levels? | KYAT1 knockout cell line |
| Does a point mutation in the active site alter substrate specificity? | CRISPR point mutation knock-in |
| Can we tag KYAT1 for localization studies? | Knock-in of fluorescent tag |
| Does overexpression of KYAT2 protect against excitotoxicity? | Overexpression stable cell line |
| What is the role of KYAT3 in mitochondrial metabolism? | Mitochondria-targeted knockout |
| Can we screen for modulators of KAT activity? | CRISPR library screening |
How to Study the L-kynurenine:2-oxoglutarate transaminase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled substrate assay | Enzyme activity | Kinetic studies |
| RNA-seq | Gene expression | Tissue-specific expression |
| LC-MS metabolomics | Metabolite levels | Pathway flux |
| CRISPR knockout | Gene function | Loss-of-function studies |
| CRISPR knock-in | Protein tagging | Localization studies |
| Overexpression | Gain-of-function | Rescue experiments |
| Western blot | Protein levels | Validation of expression |
| Immunohistochemistry | Tissue localization | Brain region mapping |
Enzymatic Activity Assays
Kynurenine aminotransferase activity can be measured using radiolabeled [3H]kynurenine as a substrate, followed by separation and quantification of products. This method allows for precise determination of enzyme kinetics and substrate specificity.
Gene Expression Analysis
RNA-seq and qPCR can quantify the expression of KAT isoenzymes across tissues and conditions. This helps identify tissue-specific regulation and splice variants.
Proteomics and Metabolomics
Mass spectrometry-based metabolomics can measure kynurenine pathway metabolites, including kynurenic acid and xanthurenate, providing a readout of KAT activity in biological samples.
CRISPR-Based Functional Genomics
CRISPR knockout, knock-in, and overexpression models enable causal interrogation of KAT genes in cellular and animal models, linking genotype to phenotype.
How CRISPR Can Be Used to Study GO:0016212 L-kynurenine:2-oxoglutarate transaminase activity
Knockout
CRISPR knockout of KYAT1, KYAT2, or KYAT3 can abolish kynurenine aminotransferase activity, allowing researchers to study the consequences on kynurenic acid production and downstream pathways. Such models are valuable for validating the role of specific isoenzymes in neurological functions.
Point Mutation
Introducing point mutations in the active site of KAT genes can dissect catalytic residues and cofactor binding. For example, mutating the PLP-binding lysine can render the enzyme inactive, providing insights into mechanism.
Knock-in
Knock-in of epitope tags or fluorescent proteins allows for real-time tracking of KAT localization and interactions. This approach can reveal tissue-specific distribution and subcellular localization.
Overexpression
Overexpression of KAT isoenzymes in cell lines or animal models can elevate kynurenic acid levels, enabling studies on neuroprotection and metabolic effects. This is particularly useful for testing therapeutic hypotheses.
How EDITGENE Supports L-kynurenine:2-oxoglutarate transaminase activity Research
Researchers studying L-kynurenine:2-oxoglutarate transaminase activity-related genes often need to determine whether a candidate gene is causally involved in kynurenine metabolism, neuroprotection, or disease. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for L-kynurenine:2-oxoglutarate transaminase activity research.
Frequently Asked Questions About L-kynurenine:2-oxoglutarate transaminase activity
What is GO:0016212?
GO:0016212 is the Gene Ontology term for L-kynurenine:2-oxoglutarate transaminase activity, an enzymatic reaction that converts L-kynurenine to kynurenate using 2-oxoglutarate.
What genes are involved in L-kynurenine:2-oxoglutarate transaminase activity?
The main genes are KYAT1, KYAT2, and KYAT3, which encode kynurenine aminotransferase isoenzymes.
What is the function of kynurenine aminotransferase?
It catalyzes the transamination of kynurenine to kynurenic acid, a neuroactive metabolite.
Which diseases are associated with kynurenine aminotransferase?
Dysregulation has been linked to schizophrenia, epilepsy, and metabolic disorders.
What cofactor does kynurenine aminotransferase require?
It requires pyridoxal 5'-phosphate (PLP) as a cofactor.
How can I study kynurenine aminotransferase activity?
Enzymatic assays with radiolabeled kynurenine, metabolomics, and CRISPR-based models are common approaches.
What is the difference between KYAT1 and KYAT2?
KYAT1 and KYAT2 are distinct isoenzymes with different tissue distributions and kinetic properties.
Can CRISPR be used to study kynurenine aminotransferase?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise functional studies.
What are the products of the kynurenine aminotransferase reaction?
The products are kynurenate and L-glutamate, with xanthurenate formed from 3-hydroxykynurenine.
Where is kynurenine aminotransferase expressed?
It is expressed in brain, liver, kidney, heart, and small intestine.
Conclusion
GO:0016212, L-kynurenine:2-oxoglutarate transaminase activity, is a critical enzymatic function in the kynurenine pathway, influencing neuroactive metabolite production and broader metabolism. Its study offers insights into neurological and psychiatric disorders, and CRISPR-based models provide powerful tools for mechanistic dissection. EDITGENE's services support researchers in uncovering the roles of KAT genes and developing therapeutic strategies.
References
- 1. Noguchi T et al.. 1975. Purification and characterization of kynurenine--2-oxoglutarate aminotransferase from the liver, brain and small intestine of rats.. Biochem J 151(2):399-406 PMID: 1218085
- 2. Okuno E et al.. 1996. Kynurenine aminotransferases in the rat. Localization and characterization.. Adv Exp Med Biol 398:455-64 PMID: 8906305
- 3. Okuno E et al.. 1991. Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations.. J Neurochem 57(2):533-40 PMID: 2072101
- 4. Okuno E et al.. 1991. Two kynurenine aminotransferases in human brain.. Brain Res 542(2):307-12 PMID: 2029638
- 5. Okuno E et al.. 1993. 2-Aminoadipate-2-oxoglutarate aminotransferase isoenzymes in human liver: a plausible physiological role in lysine and tryptophan metabolism.. Enzyme Protein 47(3):136-48 PMID: 8087205
- 6. Schmidt W et al.. 1993. Characterization of human brain kynurenine aminotransferases using [3H]kynurenine as a substrate.. Neuroscience 55(1):177-84 PMID: 8350986
- 7. Baran H et al.. 1997. Kynurenic acid and kynurenine aminotransferase in heart.. Pediatr Res 41(3):404-10 PMID: 9078543
- 8. Marciano D et al.. 2009. Functional characterization of stage-specific aminotransferases from trypanosomatids.. Mol Biochem Parasitol 166(2):172-82 PMID: 19443056
